BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

Bank of America upped their price target on shares of Quest Diagnostics from $179.00 to $182.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group lifted ...

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Align Technology (ALGN-Q) from The Globe and Mail including charting and trades.

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

This was the stock's second consecutive day of losses.

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

However, Goldman Sachs raised gold price target to $3,700 an ounce by end-2025, its third such hike this year, reports said. Earlier in March, the investment bank had hiked its 2025 gold price ...